In a groundbreaking move, federal health authorities in the United States have greenlit a new sunscreen ingredient for the first time in a quarter of a century, marking a significant advancement in skin protection options for consumers. The ingredient, bemotrizinol, has long been available in Europe and other parts of the world, and its introduction promises to enhance the effectiveness of sun care products across the nation.
A Long-Awaited Approval
The Food and Drug Administration (FDA) has confirmed that bemotrizinol meets its rigorous safety standards, demonstrating minimal skin irritation and absorption. This ingredient is now deemed safe for use by adults and children aged six months and older. Initially, bemotrizinol will be marketed in the US under the brand name Parsol Shield by Dutch manufacturer DSM Nutritional Products, with the product expected to hit shelves later this year. After an exclusive 18-month period, other brands will be allowed to incorporate this innovative ingredient into their sunscreen formulations.
The slow pace of new sunscreen approvals in the US has been a longstanding issue, largely due to the FDA’s complex and often cumbersome process for updating its list of approved non-prescription drug ingredients. However, bemotrizinol is the first ingredient to successfully navigate a revised approval pathway established by Congress in 2020, which aims to expedite the introduction of new sunscreen products.
Filling a Crucial Gap
Experts in the field are hailing bemotrizinol’s approval as a vital step forward in the battle against harmful UV rays. Unlike many existing chemical-blocking ingredients, which typically protect against either UVA or UVB rays, bemotrizinol provides comprehensive protection against both. This dual-action capability means consumers can enjoy enhanced sun protection without the chalky residue often associated with mineral-based sunscreens.
David Andrews from the Environmental Working Group noted, “For decades, Americans have relied on outdated sunscreen technology while the rest of the world moved forward. The approval of bemotrizinol will help change that.” His organisation has been a persistent advocate for improved sunscreen standards and the introduction of new, effective ingredients into the market.
Current regulations require all sunscreens to protect against UVB rays, which are primarily responsible for sunburn, as well as UVA rays, which are linked to skin cancer and premature ageing. However, many available products provide inadequate protection, forcing consumers to layer different sunscreens or settle for less effective options.
A Commitment to Consumer Safety
Dr. Mike Davis, the acting director of the FDA’s drug centre, expressed the agency’s dedication to ensuring that American consumers have access to safe and effective therapies, including over-the-counter products like sunscreens. The FDA has been actively updating its sunscreen standards over the years. In 2011, it banned the misleading term “waterproof” and mandated that all sunscreens filter both UVA and UVB rays. Further proposals were made in 2021 to enhance these regulations, including capping SPF numbers and requiring stronger UVA protection, though these measures are still pending finalisation.
As bemotrizinol prepares to enter the market, it represents not just a new product, but a beacon of hope for those seeking reliable sun protection in a country where options have been limited for far too long.
Why it Matters
The approval of bemotrizinol is a significant milestone for public health, reflecting a growing recognition of the need for effective sun protection in an era when skin cancer rates continue to rise. As consumers gain access to this advanced ingredient, they will have more choices for protecting themselves and their families from the sun’s harmful rays. This development not only enhances consumer safety but also signals a shift towards modernising health regulations, ensuring that the American market aligns with global standards in skincare and sun protection.
